AGEN240517P13000
- 2.05
- 0.000.00%
Agenus Newsroom
Express News | FDA Grants Agenus Type B End-of-Phase 2 Meeting to Discuss BOT/Bal Therapy for Relapsed or Refractory Metastatic Colorectal Cancer
Merck Discontinues Testing of Experimental Skin Cancer Combo Therapy
Analysts Offer Insights on Healthcare Companies: Arvinas Holding Company (ARVN), Eledon Pharmaceuticals (ELDN) and Agenus (AGEN)
Express News | HC Wainwright & Co. Reiterates Buy on Agenus, Maintains $40 Price Target
Agenus Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/07/2024 229.49% HC Wainwright & Co. → $40 Reiterates Buy → Buy 03/18/2024 -58.81% B. Riley Securities $
Ligand Pharmaceuticals Investing in Agenus to Fund Development of Oncology Drug Candidates
Ligand Pharmaceuticals (LGND) and Agenus (AGEN) said Tuesday they have signed a royalty financing agreement to support the clinical development of Agenus' botensilimab and balstilimab, including a con
NanoViricides, TC BioPharm, Holdco Nuvo Among Healthcare Movers
Agenus Inc (AGEN) Q1 2024 Earnings: Misses Revenue and EPS Estimates Amid Strategic Developments
Earnings Flash (AGEN) AGENUS Reports Q1 Revenue $28M
07:50 AM EDT, 05/07/2024 (MT Newswires) -- Earnings Flash (AGEN) AGENUS Reports Q1 Revenue $28M
Express News | Outside CRC, Agenus Expects To Release Updated Phase 1 And 2 Data In Melanoma, Lung Cancer, Sarcoma And Pancreatic Cancer Later This Year
Express News | Agenus Q1 2024 GAAP EPS $(3.04) Beats $(3.14) Estimate, Sales $28.005M Miss $39.268M Estimate
Express News | Agenus Inc - $100M Royalty Financing Agreement With Ligand Announced
Express News | Agenus Reports First Quarter 2024 Results
Agenus 1Q Loss $63.5M >AGEN
Agenus 1Q Loss $63.5M >AGEN
Agenus Ended 1Q With a Cash and Cash Equivalent Balance of $52.9M >AGEN
Agenus Ended 1Q With a Cash and Cash Equivalent Balance of $52.9M >AGEN
Agenus | 10-Q: Quarterly report
Express News | Agenus - Companies Also Agreed to Allow Agenus to Syndicate up to an Additional $125 Mln, Potentially Bringing Total Capital Infusion up to $200 Mln
Express News | Agenus Inc - Ligand Will Also Receive a 2.625% Royalty on Future Global Net Sales Generated by BOT/Bal
Express News | Agenus Inc - Ligand's Portion of Milestones Related to Six Programs Has Potential to Exceed $400 Mln, With Royalties in Low Single Digits
Express News | Agenus Inc - Ligand Will Receive 18.75% of Future Royalties,31.875% of Future Milestone Payments Related to Six of Co's Programs